Patent · US Active

1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl) ureas as p38 MAP kinase inhibitors

US9108950B2 · kind B2 · utility

34Cited by

29References

13Claims

0Family size

Assignee

RESPIVERT LTD. · GB

Inventors

Kazuhiro Ito · London, GB
Catherine Elisabeth Charron · London, GB
John King-Underwood · Pendock, GB
Stuart Thomas Onions · Nottingham, GB
Alistair Ian Longshaw · Nottingham, GB
Rudy Laurent Maria Broeckx · Beerse, BE
Walter Ferdinand Maria Filliers · Vremde, BE
Alex Herman Copmans · Beerse, BE

Key dates

Filing date	Oct 3, 2012
Grant date	Aug 18, 2015
Priority date	—
Expiry date	Oct 3, 2032

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02A50/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

There is provided a compound of formula (I) which is an inhibitor of the family of p38 mitogen-activated protein kinase enzymes, and to its use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, such as asthma and COPD.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.